Axsome Therapeutics, Inc.
AXSM
Kedudukan dalam Saham
#2347
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Harga Saham
$159.65
Modal Pasaran
$8.36B
Perubahan (1 hari)
2.46%
Perubahan (1 tahun)
21.31%
Negara
US
Perdagangan Axsome Therapeutics, Inc. (AXSM)
Kategori
Healthcare
Pendapatan untuk Axsome Therapeutics, Inc. (AXSM)
Pendapatan pada Jun 2026 TTM: $-191.09M
Menurut laporan kewangan terkini Axsome Therapeutics, Inc., pendapatan semasa syarikat ialah $-191.09M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-238.28M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-187.13M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Axsome Therapeutics, Inc. dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-191.09M | -33.45% |
| 2024 | $-287.13M | 20.50% |
| 2023 | $-238.28M | 27.33% |
| 2022 | $-187.13M | 43.50% |
| 2021 | $-130.40M | 26.73% |
| 2020 | $-102.90M | 50.56% |
| 2019 | $-68.35M | 120.71% |
| 2018 | $-30.97M | 6.99% |
| 2017 | $-28.94M | 6.40% |
| 2016 | $-27.20M | 157.60% |
| 2015 | $-10.56M | 75.98% |
| 2014 | $-6.00M | 176.95% |
| 2013 | $-2.17M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -2,860.48% |
US
|
|
| $-3.09B | 1,515.50% |
US
|
|
| $-4.02B | 2,001.77% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,120.82% |
NL
|
